1. Saudi Arabia Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Saudi Pharmaceutical Industries & Medical Appliances Corp.

Saudi Pharmaceutical Industries & Medical Appliances Corp.

TTADAWUL:2070
27.88
SAR
-0.88
(-3.06%)
1.87EPS
15.79P/E
3.37BMarket Cap
Nov 03Next Earn
Saudi Pharmaceutical Industries & Medical Appliances Corp.
TADAWUL:2070
(Saudi Exchange)

Recent

price

27.88

P/E

ratio

15.79

div

yld

1.23%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
SAR
8.65
9.41
9.86
10.92
13.64
14.21
10.49
11.55
12.53
12.39
12.96
12.16
11.85
13.84
14.07
14.3
14.51
Revenue per Share
1.47
1.76
1.94
2.22
2.94
2.98
2.31
1.16
0.62
-3.66
1.04
0.22
-1.38
-0.42
0.21
1.54
1.79
Basic EPS, GAAP
0.98
0.62
0.85
0.05
0.4
-0.32
-0.78
1.3
-2.96
- -
-1.45
0.02
-1.48
-0.85
-3.62
1.45
0.88
Free Cash Flow per Basic Share
0.89
0.9
1.24
1.2
- -
- -
- -
- -
1.47
0.98
0.49
0.98
0.59
- -
0.02
- -
0.34
Dividend per Share
24.48
26.51
25.28
32.19
28.75
22.43
25.09
21.51
21.28
16.2
15.96
15.31
12.83
11.48
11.55
13.38
14.15
Book Value per Share
24.27
26.34
25.19
32.14
28.69
21.84
25.09
19.34
19.21
15.38
15.27
14.72
12.35
10.98
10.5
12.25
13.32
Tangible Book Value per Share
120
120
120
120
108
120
120
120
120
120
120
120
120
120
120
119
120
Basic Weighted Avg Shares
1,038
1,129
1,183
1,311
1,470
1,705
1,259
1,386
1,503
1,487
1,555
1,460
1,422
1,655
1,682
1,707
1,738
Sales/Revenue/Turnover
15.69
16.45
17.28
15.69
16.46
15.37
4.21
13.96
1.95
-5.13
9.57
2.78
-6.87
2.81
9.38
14.52
17.91
Operating Margin (%)
-7
22
30
31
- -
- -
- -
- -
53
102
87
88
89
82
85
97
92
Depreciation Expense
177
211
233
267
317
357
277
139
74
-440
125
26
-165
-51
25
184
214
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
34.37
- -
27.66
36.6
- -
868.21
55.78
4.3
7.71
Effective Tax Rate (%)
17.01
18.72
19.66
20.36
21.55
20.94
21.99
10.02
4.94
-29.58
8.02
1.81
-11.61
-3.06
1.46
10.8
12.34
Profit Margin (%)
772
858
824
873
1,022
874
1,355
1,170
885
423
1,103
823
527
498
346
516
621
Working Capital
- -
- -
- -
- -
- -
- -
- -
682
479
672
662
435
399
587
471
467
490
LT Debt
2,957
3,203
3,059
3,898
3,493
2,727
3,135
2,815
2,756
2,114
2,071
1,993
1,693
1,516
1,531
1,762
1,846
Total Equity
7.21
6.84
6.4
5.83
6.43
7.88
1.67
5.66
1.41
- -
3.46
1.1
- -
-15.22
2.18
8.29
8.69
Return on Invested Capital (%)
6.85
6.87
6.84
7.15
7.99
10.42
9.53
4.62
3.18
- -
4.87
1.63
- -
-23.39
2.1
8.52
8.78
Return on Capital (%)
6.9
6.91
7.49
7.74
8.67
11.63
9.71
4.97
2.89
-19.56
6.47
1.41
-9.78
-3.48
1.78
12.39
13.43
Return on Common Equity (%)

Capital Structure

SAR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
967
925
961
LT Borrowings
462
344
486
LT Finance Leases
5
4
4
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
119
119
119
Market Capitalization
3,110
3,636
3,373

Working Capital

SAR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
2,376
2,291
2,388
Cash, Cash Equivalents & STI
384
342
371
Accounts Receivable, Net
1,176
1,192
1,301
Inventories
611
588
533
Total Current Liabilities
1,860
1,820
1,767
Payables & Accruals
- -
- -
- -
ST Debt
967
925
961
Deferred Revenue
- -
- -
- -

Growth Rates

SAR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-3.59%
-2.64%
15.07%
Free Cash Flow
-10,204.83%
-1,264.39%
-139.88%
Net Income, GAAP
-130.87%
-73.85%
651.43%
Sales/Revenue/Turnover
0.67%
2.15%
1.47%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SAR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
476
373
447
386
1,682
2025
485
401
415
406
1,707
2026
424
493
- -
- -
- -

Quarterly Earnings Per Share

SAR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.3
0.15
-0.09
-0.3
0.21
2025
0.59
0.28
0.35
0.32
1.54
2026
0.55
0.57
- -
- -
- -

Quarterly Dividends Per Share

SAR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.01
- -
0.01
0.02
2025
- -
- -
- -
- -
- -
2026
- -
0.34
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO) manufactures, develops, markets, and sells generic pharmaceuticals and medical appliances in Saudi Arabia and across 16 countries in the MENA region. Founded in 1986 and headquartered in Riyadh, the company operates as a Saudi joint-stock entity with SAR 1.2 billion in paid-up capital, producing high-quality medicines spanning more than 60 therapeutic classes including antibiotics; non-steroidal anti-inflammatory drugs (NSAIDs); treatments for nausea and vomiting; hypertension medications; antifungals; diabetes drugs; asthma therapies; antivirals; peptic ulcer disease remedies; cough and cold preparations; as well as recent expansions into hepatitis, oncology, biosimilars, and high-potent drugs. SPIMACO maintains advanced manufacturing facilities such as the Al-Qassim Pharmaceutical Plant and serves local and export markets through strategic investments in joint-stock and limited liability companies both domestically and internationally. In recent developments, SPIMACO launched a new oncology and high-potent drug plant in July 2025 at a cost of SAR 272 million, capable of producing over 300 million units annually and targeting a market share increase from under 1% to 10% in cancer drugs, with first commercial batches in production; the company plans to register over eight new drugs in 2025 and more than 15 thereafter while expanding into Africa and Europe. SPIMACO secured a SAR 200 million Shariah-compliant loan from Saudi National Bank in September 2025 to fund operations and raw material purchases, reported doubled Q2 2025 net profits to SAR 36 million, and formed key partnerships including a licensing deal with Boston Oncology in October 2025 for local oncology product manufacturing in two phases, alongside prior strategic alliances and acquisitions such as Osmopharm, Dammam Pharmaceutical Company, and collaborations with CanSinoBIO, Sinopharm, RecBio, and Merck Sharp & Dohme International.